Notch-directed microenvironment reprogramming in myeloma: A single path to multiple outcomes

Leukemia

Volumn 27, Issue 5, 2013, Pages 1009-1018

  Colombo, M ^a   Mirandola, L ^a   Platonova, N ^a   Apicella, L ^a   Basile, A ^a   Figueroa, A J ^b   Cobos, E ^b   Chiriva Internati, M ^b   Chiaramonte, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

adhesion; angiogenesis; cancer stem cells; multiple myeloma; Notch; osteolysis

Indexed keywords

NOTCH RECEPTOR;

ANGIOGENESIS; CANCER STEM CELL; EXTRACELLULAR MATRIX; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL;

BONE AND BONES; BONE MARROW CELLS; CELL ADHESION; CELL MOVEMENT; DISEASE PROGRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOLYSIS; RECEPTORS, CXCR4; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84877636998     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.6     Document Type: Review

References (120)

1. Ruiz-Arguelles GJ, Ruiz-Delgado GJ. On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS). Int J Hematol 2012; 3: 3.
2. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999; 13: 1181-1202.
3. Harousseau JL, Shaughnessy Jr J, Richardson P. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2004 237-256.
4. Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012; 119: 5374-5383.
5. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010; 28: 830-834.
6. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004; 104: 3697-3704.
7. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511-3515.
8. Mirandola L, Comi P, Cobos E, Kast WM, Chiriva-Internati M, Chiaramonte R. Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett 2011; 308: 1-13.
9. Nefedova Y, Gabrilovich D. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat 2008; 11: 210-218.
10. Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B et al. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia 2012; 26: 1402-1405.
11. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248-250.
12. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
13. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
14. Moulopoulos LA, Dimopoulos MA, Kastritis E, Christoulas D, Gkotzamanidou M, Roussou M et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol 2012; 14: 23258.
15. Ghoshal P, Nganga AJ, Moran-Giuati J, Szafranek A, Johnson TR, Bigelow AJ et al. Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res 2009; 69: 4380-4387.
16. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004; 103: 3503-3510.
17. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008; 111: 2220-2229.
18. Takeuchi T, Adachi Y, Ohtsuki Y. Skeletrophin, a novel ubiquitin ligase to the intracellular region of Jagged-2, is aberrantly expressed in multiple myeloma. Am J Pathol 2005; 166: 1817-1826.
19. Kim SY, Min HJ, Park HK, Oh B, Kim TY, She CJ et al. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 810-820.
20. Chiaramonte R, Basile A, Tassi E, Calzavara E, Cecchinato V, Rossi V et al. A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett 2005; 219: 113-120.
21. Chiaramonte R, Calzavara E, Balordi F, Sabbadini M, Capello D, Gaidano G et al. Differential regulation of Notch signal transduction in leukaemia and lymphoma cells in culture. J Cell Biochem 2003; 88: 569-577.
22. Chiron D, Maiga S, Descamps G, Moreau P, Le Gouill S, Marionneau S et al. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis 2012; 48: 247-253.
23. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
24. Van Riet I. Homing mechanisms of myeloma cells. Pathol Biol 1999; 47: 98-108.
25. Van Riet I, Vanderkerken K, de Greef C, Van Camp B. Homing behaviour of the malignant cell clone in multiple myeloma. Med Oncol 1998; 15: 154-164.
26. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012; 24: 24.
27. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011; 11: 597-606.
28. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708-2717.
29. Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006; 23: 291-300.
30. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003; 17: 203-210.
31. Trentin L, Miorin M, Facco M, Baesso I, Carraro S, Cabrelle A et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 2007; 138: 594-602.
32. Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 2008; 25: 325-334.
33. Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005; 33: 272-278.
34. Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C et al. CC-chemokine ligand 20/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 2008; 68: 6840-6850.
35. Paiva B, Perez-Andres M, Vidriales MB, Almeida J, de las Heras N, Mateos MV et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia 2011; 25: 697-706.
36. Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 2012; 22: 22.
37. Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 2010; 95: 776-784.
38. Hoshino N, Katayama N, Shibasaki T, Ohishi K, Nishioka J, Masuya M et al. A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes. J Leukoc Biol 2005; 78: 921-929.
39. Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M et al. Notch1 regulates chemotaxis and proliferation by controlling the chemokine receptors 5 and 9 in T-cell acute lymphoblastic leukemia. J Pathol 2011; 7: 10.
40. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009; 459: 1000-1004.
41. Maerki S, Ceredig R, Rolink A. Induction of chemokine receptor expression during early stages of T cell development. Immunol Lett 2006; 104: 110-117.
42. Wang YC, Hu XB, He F, Feng F, Wang L, Li W et al. Lipopolysaccharide- induced maturation of bone marrow-derived dendritic cells is regulated by notch signaling through the up-regulation of CXCR4. J Biol Chem 2009; 284: 15993-16003.
43. Wang L, Wang YC, Hu XB, Zhang BF, Dou GR, He F et al. Notch-RBP-J signaling regulates the mobilization and function of endothelial progenitor cells by dynamic modulation of CXCR4 expression in mice. PLoS One 2009; 4: e7572.
44. Mirandola L, Apicella L, Colombo M, Yuefei Yu, Berta DG, Platonova N et al. Anti- Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia; doi.10.1038/leu. 2013.27.
45. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006; 34: 1289-1295.
46. Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 2009; 24: 1150-1161.
47. Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005; 65: 1700-1709.
48. Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006; 91: 200-206.
49. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000; 106: 1331-1339.
50. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
51. Wright N, de Lera TL, Garcia-Moruja C, Lillo R, Garcia-Sanchez F, Caruz A et al. Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 2003; 102: 1978-1984.
52. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694.
53. Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res 2006; 12: 6973-6977.
54. Azab AK, Runnels JM, Pitsillides C, Moreau A-S, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
55. Mirandola L, Colombo M, Carluccio S, Platova N, Comi P, Cobos E et al. Notch1 produces a deregulation of CXCR4/SDF-1 chemokine signaling in multiple myeloma cells J Immunol 2011; 186: (abstract [149.112]).
56. Hodkinson PS, Elliott PA, Lad Y, McHugh BJ, MacKinnon AC, Haslett C et al. Mammalian NOTCH-1 activates b1 integrins via the small GTPase R-Ras. J Biol Chem 2007; 282: 28991-29001.
57. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor- 1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001; 97: 346-351.
58. Parmo-Cabanas M, Bartolome RA, Wright N, Hidalgo A, Drager AM, Teixido J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 2004; 294: 571-580.
59. Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004; 18: 976-982.
60. Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase- 9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997; 90: 1649-1655.
61. Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 2009; 15: 452-459.
62. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006; 66: 2778-2784.
63. De Raeve H, Van Marck E, Van Camp B, Vanderkerken K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol 2004; 19: 935-950.
64. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636.
65. de Angelis MH, McLntyre J, Gossler A. Maintenance of somite borders in mice requires the Delta homologue Dll1. Nature 1997; 386: 717-721.
66. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann NY Acad Sci 1997; 826: 213-217.
67. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16: 196-208.
68. Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol 2004; 57: 856-860.
69. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2. secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073.
70. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444: 1083-1087.
71. Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res 2007; 100: 1556-1568.
72. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445: 776-780.
73. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found Symp 2007; 283: 106-120.
74. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007; 67: 11244-11253.
75. Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol 2010; 149: 311-321.
76. Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol 2011; 94: 321-333.
77. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
78. Kibler C, Schermutzki F, Waller HD, Timpl R, Muller CA, Klein G. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 1998; 5: 307-323.
79. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A et al. Myeloma cellosteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007; 13: 816-823.
80. Juarez P, Guise TA. TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone 2011; 48: 23-29.
81. Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, Overdijk MB et al. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica 2011; 96: 1653-1661.
82. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wntsignaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
83. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98: 11581-11586.
84. Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P. Stromal cellderived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 2005; 36: 840-853.
85. Hirbe AC, Rubin J, Uluckan O, Morgan EA, Eagleton MC, Prior JL et al. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci USA 2007; 104: 14062-14067.
86. Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E. Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 2008; 149: 3890-3899.
87. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F et al. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem 2008; 283: 6509-6518.
88. Fukushima H, Nakao A, Okamoto F, Shin M, Kajiya H, Sakano S et al. The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol 2008; 28: 6402-6412.
89. Yamada T, Yamazaki H, Yamane T, Yoshino M, Okuyama H, Tsuneto M et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. Blood 2003; 101: 2227-2234.
90. Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S, Yagita H. Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res Ther 2012; 14: R45.
91. Schwarzer R, Kaiser M, Acikgoez O, Heider U, Mathas S, Preissner R et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia 2008; 22: 2273-2277.
92. Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 1999; 66: 981-988.
93. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2: 46-53.
94. Hue S, Kared H, Mehwish Y, Mouhamad S, Balbo M, Levy Y. Notch activation on effector T cells increases their sensitivity to Treg cell-mediated suppression through upregulation of TGF-betaRII expression. Eur J Immunol 2012; 14: 201142330.
95. Rutz S, Janke M, Kassner N, Hohnstein T, Krueger M, Scheffold A. Notch regulates IL-10 production by T helper 1 cells. Proc Natl Acad Sci USA 2008; 105: 3497-3502.
96. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115: 5385-5392.
97. Keerthivasan S, Suleiman R, Lawlor R, Roderick J, Bates T, Minter L et al. Notch signaling regulates mouse and human Th17 differentiation. J Immunol 2011; 187: 692-701.
98. Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68: 160-166.
99. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992-2998.
100. Cook G, Campbell JD. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev 1999; 13: 151-162.
101. Wolfe MS, Citron M, Diehl TS, Xia W, Donkor IO, Selkoe DJ. A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity. J Med Chem 1998; 41: 6-9.
102. Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA 2000; 97: 6138-6143.
103. Bihel F, Das C, Bowman MJ, Wolfe MS. Discovery of a subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem 2004; 47: 3931-3933.
104. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 2006; 319: 924-933.
105. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435: 959-963.
106. Wolfe MS. gamma-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem 2012; 1: 89-98.
107. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-358.
108. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.
109. Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11: 1565-1575.
110. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464: 1052-1057.
111. Aste-Amezaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 2010; 5: e9094.
112. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462: 182-188.
113. Xia W, Wong ST, Hanlon E, Morin P. gamma-Secretase modulator in Alzheimer's disease: shifting the end. J Alzheimers Dis 2012; 18: 18.
114. Nickoloff BJ, Qin JZ, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ 2002; 9: 842-855.
115. Alderton GK. Leukaemia: Notch has commitment issues. Nat Rev Cancer 2011; 11: 385.
116. Elyaman W, Bradshaw EM, Wang Y, Oukka M, Kivisakk P, Chiba S et al. JAGGED1 and delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis. J Immunol 2007; 179: 5990-5998.
117. Rodilla V, Villanueva A, Obrador-Hevia A, Robert-MorenoÀ, Fernández-Majada V, Grilli A et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci 2009; 106: 6315-6320.
118. Mirandola LA, Colombo L, Carluccio M, Platova S, Comi N, Cobos P et al. produces a deregulation of CXCR4/SDF-1 chemokine signaling in multiple myeloma cells. J Immunol 2011; 186: 112.
119. Wongchana W, Palaga T. Direct regulation of interleukin-6 expression by Notch signaling in macrophages. Cell Mol Immunol 2012; 9: 155-162.
120. Yao H, Duan M, Hu G, Buch S. Platelet-derived growth factor B chain is a novel target gene of cocaine-mediated Notch1 signaling: implications for HIVassociated neurological disorders. J Neurosci 2011; 31: 12449-12454.